Compositions and methods for treatment of SARS-COV-2
AssigneePhenom Pharmaceuticals, LLC
InventorMichelle Lorraine Rivera
Life of this patent
Estimating the term…
Abstract
Disclosed herein are formulations comprising recombinant human angiotensin converting enzyme 2 (rhACE-2) and a cellulose derivative for the prevention and treatment of a coronavirus infection. Methods and kits are also provided herein.
Claims14
A method of treating a subject infected with or at risk of being infected with a coronavirus, the method comprising administering to the subject a therapeutically effective amount of a formulation comprising:
- (a) a recombinant angiotensin converting enzyme 2 (rACE-2) protein that specifically binds to a coronavirus protein, wherein the rACE-2 protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2;
- (b) a cellulose derivative selected from hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), or a combination thereof;
- and
- (c) an excipient selected from a glycol alcohol, a sugar alcohol, an acid, an ester, or any combination thereof, wherein the rACE-2 protein is at a concentration of about 2 percent weight/weight (w/w).
A method of treating a subject infected with or at risk of being infected with a coronavirus, the method comprising administering to the subject a therapeutically effective amount of a formulation comprising:
- (a) a recombinant angiotensin converting enzyme 2 (rACE-2) protein that specifically binds to a coronavirus protein, wherein the rACE-2 protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2;
- (b) a cellulose derivative selected from hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), or a combination thereof;
- and
- (c) a glycol alcohol at a concentration of about 1 percent w/w to about 10 percent w/w, wherein the glycol alcohol is an excipient.
A method of treating a subject infected with or at risk of being infected with a coronavirus, the method comprising administering to the subject a therapeutically effective amount of a formulation comprising:
- (a) a recombinant angiotensin converting enzyme 2 (rACE-2) protein that specifically binds to a coronavirus protein, wherein the rACE-2 protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2;
- (b) a cellulose derivative selected from hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), or a combination thereof;
- and
- (c) mannitol, wherein the mannitol is an excipient.
A method of treating a subject infected with or at risk of being infected with a coronavirus, the method comprising administering to the subject a therapeutically effective amount of a formulation comprising:
- (a) a recombinant angiotensin converting enzyme 2 (rACE-2) protein that specifically binds to a coronavirus protein, wherein the rACE-2 protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2;
- (b) a cellulose derivative selected from hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), or a combination thereof;
- and
- (c) sorbic acid, wherein the sorbic acid is an excipient.
A method of treating a subject infected with or at risk of being infected with a coronavirus, the method comprising administering to the subject a therapeutically effective amount of a formulation comprising:
- (a) a recombinant angiotensin converting enzyme 2 (rACE-2) protein that specifically binds to a coronavirus protein, wherein the rACE-2 protein comprises an amino acid sequence with at least 90% sequence identity to SEQ ID NO:2;
- (b) a cellulose derivative selected from hydroxypropyl cellulose (HPC), hydroxypropyl methyl cellulose (HPMC), or a combination thereof;
- and
- (c) polysorbate 20, wherein the polysorbate 20 is an excipient.
Dependencies are inferred from the claim text.